Clinical Trial Search

Primary: Clinical Performance for Left Ventricular (LV) Sensing Amplitude at Implant for CRT-D Patients — 14.4 milli volt (mV)

Primary: Proportion of Treated Subjects Who Were Free of Intra-operative Cerebrospinal Fluid (CSF) Leakage From Dural Repair During Valsalva Maneuver, CSF Leak /…

Primary: Number of Evaluable Patients With an Increase From Baseline in Hemoglobin (Hb) of ≥1.5 g/dL — 2 participants

Primary: Fever >=38C Within 32 Hours of Vaccination. — 14; 22 percentage of participants — p=0.053

Primary: Dual Energy X-ray Absorptiometry (DXA) Assessment of Lean Tissue Mass (LTM) — 53.1; 50.5 kilograms — p=<0.01

Primary: The the Size of the 8 Late-phase Skin Response — 54; 0 percentage decline from NAC-1

Primary: Recurrence-free Survival at 2 Years — 13; 10 participants

Primary: Proportion of Patients Achieving ACR20 at Week 24, Comparison Between Fostamatinib and Placebo — 36.2; 27.8; 21.1 Percentage of responders — p=0.004

Primary: Seizure Incidence — 5; 3 Participants

Primary: Percentage of Patients Needing a Dose Reduction. — 71 percentage of participants

Primary: Change From Baseline to Week 12 in Bladder Wall Thickness — 0.00; -0.29; -0.18; -0.24 mm — p=0.095

Primary: Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit — 58; 26; 3; 0 participants

Primary: Local Control at 2 Years — 97.6 percentage of subjects — p=0.013

Primary: Degree of Leakage — 4.5; 5.2; 6.4; 6.8 units on a scale

Primary: Overall Clinical Benefit From Torisel® in Chemotherapy-naïve Castration Resistant Prostate Cancer (CRPC). — 67 percentage of participants